HARALD F. STOCK, PH.D.
President & CEO
Dr. Stock is President and Chief Executive Officer of OvaScience, a role he assumed on July 1, 2016. From January 2014 until September 2015, Dr. Stock served as President and Chief Executive Officer of Malmö, Sweden based ArjoHuntleigh AB, a leading medical device company offering innovative solutions in acute and long-term care. Before joining ArjoHuntleigh and Getinge Group he was the Chief Executive Officer of Grünenthal, a privately held, international research-based pharmaceutical company, headquartered in Germany. Prior to joining Grünenthal in 2009, he was Chairman and Managing Director at DePuy, the Orthopedics Division of Johnson & Johnson. Previously, he held various positions of increasing responsibilities in local and global functions and corporate divisions of the Roche Group until 2005, when he was appointed Senior Vice President of the Global Near Patient Testing business based in Graz, Austria.
Dr. Stock served as a Board Member at the European Federation of Pharmaceutical Industries and Associations (efpia) and is a board member at immatics biotechnologies GmbH. He also previously served as Vice-Chairman of the Supervisory Board of PAION AG, was Board Observer of ConforMIS, Inc. and represented Johnson & Johnson on the Board of BVMed, the German Medical Technology Industry Association.
Dr. Stock holds a Ph.D. in Inorganic Chemistry from Ruprecht-Karls-University of Heidelberg, Germany.
PAUL W.D. CHAPMAN
Chief Operating Officer
Mr. Chapman is the Chief Operating Officer of OvaScience. He joined from ArjoHuntleigh AB, a Sweden-based leading acute and long-term care equipment company, where he served as Regional President of North America. Prior to this role, Mr. Chapman served as President and CEO of Massachusetts-based diagnostic company Quanterix, where he oversaw growth including closing a global licensing deal with BioMérieux and a Series C financing round of more than $45 million. Mr. Chapman has also held executive leadership roles at EMD Millipore and Roche.
Mr. Chapman holds a Bachelor of Science in Microbiology from the University of Western Ontario, as well as a Bachelor of Science (hons) in Immunology from the University of Guelph Ontario. He also completed the Marketing Management Program at the Richard Ivey School of Business, University of Western Ontario.
JAMES D. LUTERMAN, PH.D.
SVP, Research and Development
James D. Luterman, Ph.D., has been with OvaScience since January 2014 and most recently served as Vice President, Research & Development. He brings over 20 years of industry experience to the Company. Prior to OvaScience, Dr. Luterman was an Early Development Team Leader at Shire Human Genetic Therapies, where he led the matrix management of Development Candidates from nomination through IND. Earlier in his career he worked at Biogen and Decision Resources Group, where he developed commercial analysis and recommendations for early stage clinical development programs.
Dr. Luterman holds a B.A. in Biology and Psychology from Bucknell University and a Ph.D. in Behavioral and Neural Sciences from Rutgers, the University of New Jersey. Dr. Luterman was a postdoctoral fellow at Mount Sinai School of Medicine in NY.
REBECCA J. PETERSON
EVP, Corporate Communications
Ms. Peterson is the Executive Vice President, Corporate Communications of OvaScience. She joined from Alkermes plc., where she served as Senior Vice President, Corporate Communications, led the investor relations, public relations, product communications, patient advocacy and internal communications efforts, and oversaw the design and implementation of programs for major product approvals and launches. Prior to Alkermes, Ms. Peterson held various communications positions at Millennium Pharmaceuticals, Inc. and, earlier in her career, Ms. Peterson worked in the public affairs office at Brigham and Women’s Hospital.
Ms. Peterson holds a B.A. in Public Health, Journalism and Communications from the University of Massachusetts at Amherst and an M.A. in Health Communications from Tufts University School of Medicine and Emerson College.
EVP, Human Resources
Ms. Spinazzola is the Executive Vice President of Human Resources at OvaScience. In this role, she has accountability for all aspects of global human resources, with a strategic focus on developing the culture and talent required for OvaScience to effectively execute its strategy. Ms. Spinazzola has experience across diverse industries — life sciences, technology, media, hospitality and non-profit — and in a variety of business environments, including M&A, operating model transformations, high-growth, global expansion and downsizing. Prior to joining OvaScience, Ms. Spinazzola was the global Vice President of Human Resources at Bruker Corporation where she was recruited to build Bruker’s first, global human resources organization. Previously, Ms. Spinazzola was a key member of HR leadership teams for The Merck Group of Darmstadt, Germany, Millipore Corporation and the Boston Globe newspaper. She also plays a critical role in her family’s charity work in Boston as a Board member for the Spinazzola, Inc., a 501(c)3 dedicated to hunger relief and culinary education for the under and unemployed.
Ms. Spinazzola has a Bachelor of Arts degree from Suffolk University and a Master of Arts in Human Resource Management from Emmanuel College.
Chief Financial Officer
Mr. Jeffrey Young is the Chief Financial Officer at OvaScience. Mr. Young joined OvaScience from Transmedics, Inc., where he served as Chief Financial Officer and Treasurer, leading the finance, accounting, tax and treasury functions. Prior to Transmedics, Mr. Young was CFO and Treasurer at Lantheus Medical Imaging, Inc. While at Lantheus, an international corporation, he was responsible for multiple functions, including finance, accounting, customer service, tax and treasury. He also assisted in raising $400 million in a registered notes offering. Before Lantheus, Mr. Young served as Chief Accounting Officer, Vice President of Finance and Treasurer at Critical Therapeutics, and managed the company’s transition during its acquisition by Cornerstone BioPharma. Earlier in his career, Mr. Young held finance roles at PerkinElmer, Inc. and PricewaterhouseCoopers.
Mr. Young is a Certified Public Accountant and holds a B.S. in Business Administration from Georgetown University.